Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2020 08:30 ET | Source: Vaxart, Inc.

Vaxart Hosting Key Opinion Leader Panel Call for Investors

Title: An Oral Tablet Vaccine – A Potential Global Solution to COVID-19 and Norovirus Key topics:COVID-19: Immunity & Immunological MemoryNorovirus: Disease Burden & Prevention. The Current...
November 16, 2020 07:00 ET | Source: Vaxart, Inc.

Vaxart Announces Presentations at the Jefferies Virtual London Healthcare Conference & the Piper Sandler Annual Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather...
November 12, 2020 16:01 ET | Source: Vaxart, Inc.

Vaxart Reports Third Quarter 2020 Financial Results and Provides Business Update

Enrollment in Phase 1 for Oral COVID-19 Vaccine Trial Completed Significant viral load reduction and strong antibody responses in COVID-19 hamster challenge model Restarting the Norovirus...
November 12, 2020 08:00 ET | Source: Vaxart, Inc.

Vaxart Announces Additional Data from Hamster Challenge Study of its Oral COVID-19 Vaccine

SOUTH SAN FRANCISCO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather...
October 14, 2020 08:00 ET | Source: Vaxart, Inc.

Vaxart Announces Positive Hamster Challenge Study Data for its Oral COVID-19 Vaccine

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc., (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather...
October 13, 2020 08:00 ET | Source: Vaxart, Inc.

Vaxart Announces Dosing First Subject in Phase 1 Clinical Trial of Its Oral Tablet COVID-19 Vaccine

Open-label, dose ranging study to examine safety and immunogenicity First clinical data readouts in a few weeks SOUTH SAN FRANCISCO, Calif., Oct. 13, 2020 (GLOBE NEWSWIRE) -- Vaxart,...
September 14, 2020 08:00 ET | Source: Vaxart, Inc.

Vaxart Announces FDA Clearance of IND Application for Oral COVID-19 Vaccine and Provides Update on COVID-19 Program

Recruitment for Phase 1 clinical study expected to start this month Data from ongoing hamster challenge study expected in October SOUTH SAN FRANCISCO, Calif., Sept. 14, 2020 (GLOBE...
September 08, 2020 08:00 ET | Source: Vaxart, Inc.

Vaxart’s Oral COVID-19 Vaccine Candidate Induces Potent Systemic and Mucosal Immune Responses in Preclinical Studies

Triggering mucosal immunity may be crucial for effective protection against SARS-CoV-2 infection and transmission Vaxart’s oral tablet vaccine can overcome major challenges of injectable vaccines ...
September 03, 2020 08:00 ET | Source: Vaxart, Inc.

Vaxart, Inc. to Participate in September Virtual Investor Conferences

- H.C. Wainwright: 22nd Annual Global Investment Conference - September 14th – 16th- Sachs Associates: 20th Annual Biotech in Europe Forum - September 21st – 24th- SVB Leerink: CybeRx Series: Vaccine...
August 27, 2020 08:00 ET | Source: Vaxart, Inc.

Vaxart Appoints Karen J. Wilson to its Board of Directors

SOUTH SAN FRANCISCO, Calif., Aug. 27, 2020 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company developing oral vaccines that are administered by tablet rather...